A carregar...

A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia

Wilms’ tumor 1 (WT1) is a promising target of new immunotherapies for acute myeloid leukemia (AML) as well as for other cancers. OCV-501 is a helper peptide derived from the WT1 protein. OCV-501 induced OCV-501-specific Type 1 T-helper (Th1) responses dose-dependently and stimulated helper activity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Main Authors: Kobayashi, Yukio, Sakura, Toru, Miyawaki, Shuichi, Toga, Kazuyuki, Sogo, Shinji, Heike, Yuji
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5489634/
https://ncbi.nlm.nih.gov/pubmed/28321480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-017-1981-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!